Bunkerhill Health lands $25M Series B for hospital AI agents

Bunkerhill Health closed a $25 million Series B, Fortune reported, led by Khosla Ventures with Sequoia, Felicis, Optum Ventures and Y Combinator also in the round. That takes total funding to $55 million and puts the company alongside the small group of health AI vendors that hospitals are actually deploying at depth, not just piloting.

The shape of the pitch is simple even if the surface is dense. Its Carebricks platform bundles operational agents that, in the company's telling, handle 'long wait times to missed follow-ups to paperwork backlogs,' together with nine FDA-cleared clinical AI algorithms, including one that detects silent heart valve disease early and another that assesses osteoporosis risk. Bunkerhill says 15 health systems now use it, including Cleveland Clinic, Mayo Clinic, Ballad Health, Intermountain Health, Sentara Health, Endeavor Health and The University of Texas Medical Branch. At UTMB alone, 22 of its agents are deployed, which is the number in this story worth staring at longest, because it is the difference between a logo slide and an actual integration.

CEO and co-founder Nishith Khandwala, who started the company with David Eng in 2019, gave Fortune the line that will follow him around this cycle: 'We don't need superintelligence to solve our biggest problems. We need average intelligence.' It is a deliberate poke at the frontier-lab framing, and it doubles as a go-to-market argument aimed at CIOs. Khandwala's other line is sharper on the commercial side: 'Why should a hospital need to work with 100 different companies to solve 100 different problems?'

The honest caveat is what the reporting does not give you. The valuation is undisclosed, there is no revenue figure, and the article does not cite independent outcome data on any of the nine cleared algorithms. It also does not break out how many of the 15 named systems are paid enterprise contracts versus pilots, which is the number that separates a rising healthcare AI vendor from a rising acquisition target. The other thing worth watching is Optum Ventures at the table. UnitedHealth's investment arm sitting next to Khosla and Sequoia is useful capital and useful distribution, and it also gives the parent an unusually good view of a category it could plausibly build into itself.

The forward bet here is a boring one, and boring is arguably the point. If Bunkerhill can turn 22 agents at UTMB into that depth across every anchor customer, it becomes the vendor that quietly took the mid-tier of hospital AI while the rest of the field was demoing chatbots.